Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Safety Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women between 40 and 65 years of age with hormone therapy indication (symptoms and need for treatment)~* Non-hysterectomized women.~Exclusion Criteria:~* Usual exclusion criteria for hormone therapy apply.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891) (Type: EXPERIMENTAL): One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
- 0.5mg NETA / 1.0mg E2 (Activella) (Type: ACTIVE_COMPARATOR): One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).